Author Archives: admin
Induced Pluripotent Stem Cells (iPSCs)-Roles in Regenerative Therapies …
Title & authors Abstract Conflict of interest statement Figures Similar articles Cited by References Publication types MeSH terms Related information Grant support LinkOut - more resources
Review
Affiliations Expand
Item in Clipboard
Review
Mourad A M Aboul-Soudet al. Cells. 2021.
Display options
Format Abstract PubMed PMID
Item in Clipboard
Display options
Format Abstract PubMed PMID
The discovery of induced pluripotent stem cells (iPSCs) has made an invaluable contribution to the field of regenerative medicine, paving way for identifying the true potential of human embryonic stem cells (ESCs). Since the controversy around ethicality of ESCs continue to be debated, iPSCs have been used to circumvent the process around destruction of the human embryo. The use of iPSCs have transformed biological research, wherein increasing number of studies are documenting nuclear reprogramming strategies to make them beneficial models for drug screening as well as disease modelling. The flexibility around the use of iPSCs include compatibility to non-invasive harvesting, and ability to source from patients with rare diseases. iPSCs have been widely used in cardiac disease modelling, studying inherited arrhythmias, neural disorders including Alzheimer's disease, liver disease, and spinal cord injury. Extensive research around identifying factors that are involved in maintaining the identity of ESCs during induction of pluripotency in somatic cells is undertaken. The focus of the current review is to detail all the clinical translation research around iPSCs and the strength of its ever-growing potential in the clinical space.
Keywords: disease; drug screening; embryo; induced pluripotent stem cells; modelling.
The authors declare that they have no conflict of interest.
Figure 1
Showing the process of progression
Figure 1
Showing the process of progression and generating iPSC cells. Detailed description of creating
Showing the process of progression and generating iPSC cells. Detailed description of creating iPSCs with reprogramming factors and differentiating them into a variety of cell types.
Figure 2
Schematic representation on derivation and
Figure 2
Schematic representation on derivation and assay for human iPSCs. Detailed schematic representation of
Schematic representation on derivation and assay for human iPSCs. Detailed schematic representation of derivation of iPSC with the various assays to evaluate the developmental efficiency.
Figure 3
Process of liver development and
Figure 3
Process of liver development and hepatic differentiation from hiPSCs. The process of isolated
Process of liver development and hepatic differentiation from hiPSCs. The process of isolated cells from patients can be cultured and reprogrammed into patient-specific hiPSCs and quick comparison from natural liver development.
Skalova S, Svadlakova T, Shaikh Qureshi WM, Dev K, Mokry J. Skalova S, et al. Int J Mol Sci. 2015 Feb 13;16(2):4043-67. doi: 10.3390/ijms16024043. Int J Mol Sci. 2015. PMID: 25689424 Free PMC article. Review.
Ohnuki M, Takahashi K. Ohnuki M, et al. Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20140367. doi: 10.1098/rstb.2014.0367. Philos Trans R Soc Lond B Biol Sci. 2015. PMID: 26416678 Free PMC article. Review.
Valdimarsdttir G, Richter A. Valdimarsdttir G, et al. Laeknabladid. 2015 Dec;101(12):581-6. doi: 10.17992/lbl.2015.12.56. Laeknabladid. 2015. PMID: 26656400 Review. Icelandic.
Parrotta EI, Scalise S, Scaramuzzino L, Cuda G. Parrotta EI, et al. Int J Mol Sci. 2019 Nov 16;20(22):5760. doi: 10.3390/ijms20225760. Int J Mol Sci. 2019. PMID: 31744081 Free PMC article. Review.
Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, Ikeda E, Yamanaka S, Miura K. Okano H, et al. Circ Res. 2013 Feb 1;112(3):523-33. doi: 10.1161/CIRCRESAHA.111.256149. Circ Res. 2013. PMID: 23371901 Review.
Ng WC, Lokanathan Y, Baki MM, Fauzi MB, Zainuddin AA, Azman M. Ng WC, et al. Biomedicines. 2022 Nov 30;10(12):3082. doi: 10.3390/biomedicines10123082. Biomedicines. 2022. PMID: 36551838 Free PMC article. Review.
Shakir S, Hackett TL, Mostao-Guidolin LB. Shakir S, et al. Front Bioeng Biotechnol. 2022 Oct 28;10:1011800. doi: 10.3389/fbioe.2022.1011800. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36394026 Free PMC article. Review.
Alberti G, Russo E, Corrao S, Anzalone R, Kruzliak P, Miceli V, Conaldi PG, Di Gaudio F, La Rocca G. Alberti G, et al. Biomedicines. 2022 Nov 5;10(11):2822. doi: 10.3390/biomedicines10112822. Biomedicines. 2022. PMID: 36359342 Free PMC article. Review.
Linkova DD, Rubtsova YP, Egorikhina MN. Linkova DD, et al. Cells. 2022 Aug 29;11(17):2691. doi: 10.3390/cells11172691. Cells. 2022. PMID: 36078098 Free PMC article. Review.
Li XW, Lu YY, Zhang SY, Sai NN, Fan YY, Cheng Y, Liu QS. Li XW, et al. Front Pharmacol. 2022 Jun 22;13:926123. doi: 10.3389/fphar.2022.926123. eCollection 2022. Front Pharmacol. 2022. PMID: 35814256 Free PMC article.
Show all 116 references
Cite
Format: AMA APA MLA NLM
Read more:
Induced Pluripotent Stem Cells (iPSCs)-Roles in Regenerative Therapies ...
Induced pluripotent stem cell technology: a decade of progress
Title & authors Abstract Conflict of interest statement Figures Similar articles Cited by Publication types MeSH terms Grant support LinkOut - more resources
Review
Affiliations Expand
Item in Clipboard
Review
Yanhong Shiet al. Nat Rev Drug Discov. 2017 Feb.
Display options
Format Abstract PubMed PMID
Item in Clipboard
Display options
Format Abstract PubMed PMID
Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago, enormous progress has been made in stem cell biology and regenerative medicine. Human iPSCs have been widely used for disease modelling, drug discovery and cell therapy development. Novel pathological mechanisms have been elucidated, new drugs originating from iPSC screens are in the pipeline and the first clinical trial using human iPSC-derived products has been initiated. In particular, the combination of human iPSC technology with recent developments in gene editing and 3D organoids makes iPSC-based platforms even more powerful in each area of their application, including precision medicine. In this Review, we discuss the progress in applications of iPSC technology that are particularly relevant to drug discovery and regenerative medicine, and consider the remaining challenges and the emerging opportunities in the field.
Conflict of Interest
J.C.W. is a co-founder of Stem Cell Theranostics. S.Y. is a scientific advisor of iPS Academia Japan without salary. The other authors declare no conflict of interest.
Figure 1
A schematic for human iPSC-based
Figure 1
A schematic for human iPSC-based disease modeling. Human iPSCs are derived from individual
A schematic for human iPSC-based disease modeling. Human iPSCs are derived from individual patients and differentiated into specific cell types. To develop new therapies, the resultant cells are used to observe disease-specific phenotypes and identify novel pathological mechanisms,. Human iPSC-based disease modeling with patient-specific cells now provides an exciting new approach for the development of personalized diagnosis and medicine.
Figure 2
A schematic for human iPSCs-based
Figure 2
A schematic for human iPSCs-based cell therapy. Human iPSC-based cell therapy development usually
A schematic for human iPSCs-based cell therapy. Human iPSC-based cell therapy development usually includes the following steps: 1) Collect somatic cells from patients and culture somatic cells from affected patients; 2) Reprogram patient somatic cells into iPSCs; 3) Use genome editing technology or viral transduction method to repair patient iPSCs and turn them into genetically corrected iPSCs; 4) Differentiate the corrected iPSCs into desired cell types to serve as genetically matched healthy donor cells; 5) Perform quality control test for cell identity, purity, activity, and safety; and 6) Transplant the genetically matched healthy cells into patients for cell therapy.
Doss MX, Sachinidis A. Doss MX, et al. Cells. 2019 Apr 30;8(5):403. doi: 10.3390/cells8050403. Cells. 2019. PMID: 31052294 Free PMC article. Review.
Wang F, Kong J, Cui YY, Liu P, Wen JY. Wang F, et al. Chin Med J (Engl). 2018 Apr 5;131(7):852-856. doi: 10.4103/0366-6999.228231. Chin Med J (Engl). 2018. PMID: 29578130 Free PMC article. Review.
Wattanapanitch M. Wattanapanitch M. Stem Cells Int. 2019 May 2;2019:5171032. doi: 10.1155/2019/5171032. eCollection 2019. Stem Cells Int. 2019. PMID: 31191673 Free PMC article. Review.
Nsair A, MacLellan WR. Nsair A, et al. Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):324-30. doi: 10.1016/j.addr.2011.01.013. Epub 2011 Mar 1. Adv Drug Deliv Rev. 2011. PMID: 21371511 Free PMC article. Review.
Cai CY, Meng FL, Rao L, Liu YY, Zhao XL. Cai CY, et al. Yi Chuan. 2020 Nov 20;42(11):1042-1061. doi: 10.16288/j.yczz.20-235. Yi Chuan. 2020. PMID: 33229312 Review. Chinese.
Pilipovi K, Harej Hrka A, Kui N, Mri-Peli J. Pilipovi K, et al. Biomedicines. 2022 Dec 29;11(1):94. doi: 10.3390/biomedicines11010094. Biomedicines. 2022. PMID: 36672601 Free PMC article. Review.
Lien CY, Chen TT, Tsai ET, Hsiao YJ, Lee N, Gao CE, Yang YP, Chen SJ, Yarmishyn AA, Hwang DK, Chou SJ, Chu WC, Chiou SH, Chien Y. Lien CY, et al. Cells. 2023 Jan 4;12(2):211. doi: 10.3390/cells12020211. Cells. 2023. PMID: 36672144 Free PMC article.
Akbarzadeh A, Sobhani S, Soltani Khaboushan A, Kajbafzadeh AM. Akbarzadeh A, et al. Bioengineering (Basel). 2023 Jan 12;10(1):106. doi: 10.3390/bioengineering10010106. Bioengineering (Basel). 2023. PMID: 36671678 Free PMC article. Review.
Han JL, Entcheva E. Han JL, et al. Stem Cell Rev Rep. 2023 Jan 19:1-20. doi: 10.1007/s12015-023-10506-4. Online ahead of print. Stem Cell Rev Rep. 2023. PMID: 36656467 Free PMC article. Review.
Mohd Satar A, Othman FA, Tan SC. Mohd Satar A, et al. World J Stem Cells. 2022 Dec 26;14(12):851-867. doi: 10.4252/wjsc.v14.i12.851. World J Stem Cells. 2022. PMID: 36619694 Free PMC article.
Cite
Format: AMA APA MLA NLM
Read more:
Induced pluripotent stem cell technology: a decade of progress
Pluripotent embryonic stem cells and multipotent adult germline stem …
Title & authors Abstract Similar articles Cited by Publication types MeSH terms Related information LinkOut - more resources . 2010 Nov;16(11):846-55. doi: 10.1093/molehr/gaq060. Epub 2010 Jul 12.
Affiliations Expand
Item in Clipboard
S Meyeret al. Mol Hum Reprod. 2010 Nov.
Display options
Format Abstract PubMed PMID
Item in Clipboard
Display options
Format Abstract PubMed PMID
DNA microarray analysis was performed with mouse multipotent adult germline stem cells (maGSCs) and embryonic stem cells (ESCs) from different genetic backgrounds cultured under standard ESC-culture conditions and under differentiation-promoting conditions by the withdrawal of the leukemia inhibitory factor (LIF) and treatment with retinoic acid (RA). The analyzed undifferentiated cell lines are very similar based on their global gene expression pattern and show 97-99% identity dependent on the analyzed background. Only 621 genes are differentially expressed in cells derived from mouse 129SV-background and 72 genes show differences in expression in cells generated from transgenic Stra8-EGFP/Rosa26-LacZ-background. Both maGSCs and ESCs express the same genes involved in the regulation of pluripotency and even show no differences in the expression level of these genes. When comparing maGSCs with previously published signature genes of other pluripotent cell lines, we found that maGSCs shared a very similar gene expression pattern with embryonic germ cells (EGCs). Also after differentiation of maGSCs and ESCs the transcriptomes of the cell lines are nearly identical which suggests that both cell types differentiate spontaneously in a very similar way. This is the first study, at transcriptome level, to compare ESCs and a pluripotent cell line derived from an adult organism (maGSCs).
Zovoilis A, Pantazi A, Smorag L, Opitz L, Riester GS, Wolf M, Zechner U, Holubowska A, Stewart CL, Engel W. Zovoilis A, et al. Mol Hum Reprod. 2010 Nov;16(11):793-803. doi: 10.1093/molehr/gaq053. Epub 2010 Jun 21. Mol Hum Reprod. 2010. PMID: 20566704
Zovoilis A, Nolte J, Drusenheimer N, Zechner U, Hada H, Guan K, Hasenfuss G, Nayernia K, Engel W. Zovoilis A, et al. Mol Hum Reprod. 2008 Sep;14(9):521-9. doi: 10.1093/molehr/gan044. Epub 2008 Aug 12. Mol Hum Reprod. 2008. PMID: 18697907
Nolte J, Michelmann HW, Wolf M, Wulf G, Nayernia K, Meinhardt A, Zechner U, Engel W. Nolte J, et al. Differentiation. 2010 Nov-Dec;80(4-5):184-94. doi: 10.1016/j.diff.2010.08.001. Epub 2010 Sep 1. Differentiation. 2010. PMID: 20810205
Kerr CL, Shamblott MJ, Gearhart JD. Kerr CL, et al. Methods Enzymol. 2006;419:400-26. doi: 10.1016/S0076-6879(06)19016-3. Methods Enzymol. 2006. PMID: 17141064 Review.
Petitte JN, Liu G, Yang Z. Petitte JN, et al. Mech Dev. 2004 Sep;121(9):1159-68. doi: 10.1016/j.mod.2004.05.003. Mech Dev. 2004. PMID: 15296979 Review.
Han Z, Zhang Q, Zhu Y, Chen J, Li W. Han Z, et al. Stem Cells Int. 2020 Jul 6;2020:8863539. doi: 10.1155/2020/8863539. eCollection 2020. Stem Cells Int. 2020. PMID: 32695182 Free PMC article. Review.
Kalasauskas D, Sorokin M, Sprang B, Elmasri A, Viehweg S, Salinas G, Opitz L, Rave-Fraenk M, Schulz-Schaeffer W, Kantelhardt SR, Giese A, Buzdin A, Kim EL. Kalasauskas D, et al. Cancers (Basel). 2020 Mar 1;12(3):570. doi: 10.3390/cancers12030570. Cancers (Basel). 2020. PMID: 32121554 Free PMC article.
Bai Y, Zhu C, Feng M, Wei H, Li L, Tian X, Zhao Z, Liu S, Ma N, Zhang X, Shi R, Fu C, Wu Z, Zhang S. Bai Y, et al. Stem Cell Res Ther. 2018 Jul 18;9(1):200. doi: 10.1186/s13287-018-0931-0. Stem Cell Res Ther. 2018. PMID: 30021628 Free PMC article.
Imamura M, Lin ZY, Okano H. Imamura M, et al. Reprod Med Biol. 2012 Jun 19;12(1):1-14. doi: 10.1007/s12522-012-0131-z. eCollection 2013 Jan. Reprod Med Biol. 2012. PMID: 29699125 Free PMC article. Review.
Saeidi S, Shapouri F, de Iongh RU, Casagranda F, Sutherland JM, Western PS, McLaughlin EA, Familari M, Hime GR. Saeidi S, et al. PLoS One. 2018 Jan 11;13(1):e0190925. doi: 10.1371/journal.pone.0190925. eCollection 2018. PLoS One. 2018. PMID: 29324788 Free PMC article.
Cite
Format: AMA APA MLA NLM
Read more here:
Pluripotent embryonic stem cells and multipotent adult germline stem ...
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.
Read the rest here:
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.
Read more:
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced a 1-for-20 reverse split of its common stock, effective at 5:00 P.M. Eastern Time today. Beginning on February 10, 2023, the Company’s common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) on a split adjusted basis under the trading symbol “INBS”, but will trade under the following new CUSIP number: 36151G402.
Follow this link:
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.
Read the original:
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference